CHRS Q3 2025 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-83.7% YoY

Gross Profit

$8M67.8% margin

Operating Income

-$44M-383.1% margin

Net Income

-$36M-307.1% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+12.8%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$517M

Total Liabilities

$429M

Stockholders' Equity

$88M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$71M	-83.7%
Gross Profit	$8M	$50M	-84.3%
Operating Income	-$44M	-$6M	-594.1%
Net Income	-$36M	-$11M	-230.5%

Revenue Segments

Product and Service, Other

$402,000100%